Alkermes
artistry phase efficacy expansion initiated following determination of subcutaneous | Alkermes
Company
Deck Type
Sector
Industry
Deck date
June 2021
Slide
23 of 31
Similar slides by Alkermes
See diffirences between slides (animation)
Investor Day
March 2021
artistry phase efficacy expansion initiated following determination phase dose week lead in followed by combination of and either or cohorts a to a dose cohorts to dose phase efficacy expansion in solid tumors initiated at combination selected efficacy expansion in select solid tumors where previous responses were observed primary objectives safety and efficacy in combination with subcutaneous recommended phase dose administered once weekly administered once every three weeks secondary objectives include clinical profile and immunogenicity clinical pharmacodynamic effects all parts anti tumor activity phase and objective response rate and dor duration of response phase as fae | Alkermes
Related slides by other companies
BioNTech
Results
May 2021
next generation car therapy in solid tumors | BioNTech
Kymera
Investor Presentation
June 2023
phase dose and expansion trial to evaluate in adult patients with liquid and solid tumors | Kymera
Kymera
Investor Presentation
August 2023
phase dose and expansion trial to evaluate in adult patients with liquid and solid tumors | Kymera
Immatics
Investor Presentation
November 2023
phase clinical trial to evaluate targeting | Immatics
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights